From operator to API: how the future of micronisation means no more compromise
Despite industry investment in large molecule drugs, demand for small molecule active pharmaceutical ingredients (API) manufacturing remains high. Driven by…
Despite industry investment in large molecule drugs, demand for small molecule active pharmaceutical ingredients (API) manufacturing remains high. Driven by…
Test strips are a significant tool in point-of-care (POC) diagnostics for blood, urine, and glucose analysis. The rising demand for…
European manufacturers are at the forefront of the technical textiles and nonwovens market. Reports predict that the European technical textile…
Due to its geographic proximity with China, South Korea was one of the first locations hit with the Covid-19 viral…
Biosimilars - biologic drugs with a high degree of similarity to previously-approved innovator biologics, hit full steam in 2019, with…
Clinical development in oncology and immunotherapies has accelerated dramatically over the past few years. As of December 2019, over 6,000…
The regulatory environment in Australia and New Zealand offers a significant strategic opportunity for international biotech companies wanting a fast…
It is estimated that 70-80% of biotech firms still follow a study-by-study approach for their drug development program, often driven…
When bringing a drug to market, there is a range of scientific, clinical, regulatory and market access challenges that pharmaceutical…
Pharmaceuticals use some the most advanced technology in the packaging industry, setting trends that regularly trickle down to packaging standards…